Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HM10460A (HNK460) When Administered Subcutaneously to Healthy Adult Korean Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eflapegrastim (Primary)
- Indications Neutropenia
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Hanmi Pharmaceutical
- 01 May 2014 New trial record